NCT03732781 is a Phase 1, PHASE2 clinical trial of Radspherin in Peritoneal Carcinoma, sponsored by Oncoinvent Solutions AS.

Who is sponsoring NCT03732781?

NCT03732781 is sponsored by Oncoinvent Solutions AS.

What drugs are being tested in NCT03732781?

Interventions in NCT03732781: Radspherin.

What condition does NCT03732781 study?

NCT03732781 studies Peritoneal Carcinoma, Colorectal Carcinoma.

Is NCT03732781 still recruiting?

NCT03732781 is currently completed. Last updated 28 August 2025.

Last reviewed 2025-08-28 · How we verify

NCT03732781

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC

Completed Phase 1, PHASE2 Last updated 28 August 2025

What this trial tests

Phase 1, PHASE2 trial testing Radspherin in Peritoneal Carcinoma in 47 participants. Completed in 14 May 2025.

Timeline

27 May 2020

Primary endpoint
14 May 2025

14 May 2025

Quick facts

Lead sponsor	Oncoinvent Solutions AS
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	47
Start date	27 May 2020
Primary completion	14 May 2025
Estimated completion	14 May 2025
Sites	2 locations across Sweden, Norway

Drugs / interventions tested

Radspherin — full drug profile →

Conditions studied

Peritoneal Carcinoma — all drugs for Peritoneal Carcinoma →
Colorectal Carcinoma — all drugs for Colorectal Carcinoma →

Sponsor

Oncoinvent Solutions AS — full company profile →

Who can join

18 and older, any sex, with Peritoneal Carcinoma or Colorectal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1/2a open label study to evaluate the dose, safety, tolerability and efficacy of an IP α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis (PC) from colorectal carcinoma following complete CRS (cytoreduction score CC-0) and HIPEC. The study consists of three different cohorts: * Dose escalation cohorts * Repeated injection cohorts * Expansion cohort

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.
Harper MM, Kim J, Pandalai PK. · · 2022 · cited 14× · PMID 35628966 · DOI 10.3390/jcm11102840
Improved Formulation of 224Ra-Labeled Calcium Carbonate Microparticles by Surface Layer Encapsulation and Addition of EDTMP.
Li RG, Lindland K, Tonstad SK, Bønsdorff TB, et al · · 2021 · cited 11× · PMID 33946852 · DOI 10.3390/pharmaceutics13050634
First experience with 224Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study).
Larsen SG, Graf W, Mariathasan AB, Sørensen O, et al · · 2023 · cited 9× · PMID 36936230 · DOI 10.3389/fmed.2023.1070362
Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis.
Grønningsæter SR, Blakkisrud J, Selboe S, Revheim ME, et al · · 2023 · cited 5× · PMID 36844217 · DOI 10.3389/fmed.2023.1058914
Effect of Intraperitoneal 224Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy.
Thorgersen EB, Asvall J, Schjalm C, McAdam KE, et al · · 2023 · cited 1× · PMID 37574949 · DOI 10.1177/15330338231192902
Experiences and Hopes Among Patients with Colorectal Carcinoma and Peritoneal Metastases Who Are Participating in an Early-Phase Clinical Trial.
Fauske L, Bruland ØS, Holtermann A, Larsen SG. · · 2026 · PMID 41595164 · DOI 10.3390/cancers18020244

Verify or expand the search:

Other trials of Radspherin

Trials testing the same drug.

NCT06504147 — A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologo · Phase 2 · recruiting
NCT03732768 — Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis · Phase 1 · completed

Other recruiting trials for Peritoneal Carcinoma

Currently open trials in the same condition.

NCT06290193 — Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery · Phase 2 · recruiting
NCT05763199 — Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy · Phase 2 · active not recruiting
NCT05605535 — Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer · Phase 2 · active not recruiting
NCT04498117 — Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Su · Phase 3 · active not recruiting
NCT03296826 — Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03732781 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oncoinvent Solutions AS
Last refreshed: 28 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03732781.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing